Tuesday, February 2, 2021
1:39 PM EST – BioVaxys Technology Corp. : Announced that its Covid-19 vaccine candidate, BVX-0320, elicits a neutralizing antibody response against SARS-CoV-2, as evidenced by further analysis of sera samples from a preclinical animal study (also known as the “murine model study”) of its haptenized viral protein vaccine technology. Under a BioVaxys-sponsored research collaboration with The Ohio State University (“OSU”) Wexner School of Medicine, OSU researchers observed in a pooled sample that BVX-0320 elicited the production of neutralizing antibodies to SARS-CoV-2. It’s worth noting that OSU is one of the few institutions that has the laboratory capability to study live SARS-CoV-2 virus. BioVaxys Technology Corp. (C.BIOV) shares were off 5.88 percent at 0.4.
Stocks in Play: BioVaxys Technology Corp. , Tue, 02 Feb 2021 01:45:01 EST